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ABSTRACT DNA diagnostics, the detection of specific
DNA sequences, will play an increasingly important role in
medicine as the molecular basis of human disease is defined.
Here, we demonstrate an automated, nonisotopic strategy for
DNA diagnostics using amplification of target DNA segments
by the polymerase chain reaction (PCR) and the discrimination
of allelic sequence variants by a colorimetric oligonucleotide
ligation assay (OLA). We have applied the automated
PCR/OLA procedure to diagnosis ofcommon genetic diseases,
such as sickle cell anemia and cystic fibrosis (AF508 mutation),
and to genetic linkage mapping of gene segments in the human
T-cell receptor f-chain locus. The automated PCR/OLA
strategy provides a rapid system for diagnosis of genetic,
malignant, and infectious diseases as well as a powerful ap-
proach to genetic linkage mapping of chromosomes and foren-
sic DNA typing.
The study ofDNA sequence variants in humans is playing an
important role in diagnosis of genetic and malignant diseases
(1, 2). The analysis ofDNA polymorphisms also serves as the
fundamental tool in attempts to construct genetic linkage
maps (3, 4) and in forensic analyses (5, 6). Since the majority
of DNA sequence variants and polymorphisms are single
nucleotide substitutions (1, 2), diagnostic techniques must
accurately discriminate single base changes.
Single base variations in DNA sequences can be detected
by a variety oftechniques including Southern blot analysis (7)
for restriction fragment length polymorphisms, allele-specific
oligonucleotide hybridization (8), denaturing gradient gel
electrophoresis (9), chemical cleavage of mismatched het-
eroduplexes (10), conformational changes in single strands
(11), and allele-specific priming of the polymerase chain
reaction (PCR) (12-14). These techniques have several dis-
advantages for automatingDNA diagnosis, which include the
use of radioactivity, the requirement for various hybridiza-
tion conditions, and the need for electrophoresis or centrif-
ugation.
The analysis of DNA sequence variants has been greatly
facilitated by the development of rapid methods to exponen-
tially amplify specific DNA or RNA targets. Diagnostic
targets can be amplified by PCR (15-17) or by other available
methods (18-21). Amplification generates specific targets
with high signal/noise ratios and permits the use of less
sensitive nonisotopic reporters in DNA analysis.
An alternative strategy for DNA diagnosis, the oligonu-
cleotide ligation assay (OLA), employs two adjacent oligo-
nucleotides (20-mers), a 5' biotinylated probe (with its 3' end
at the nucleotide to be assayed) and a 3' reporter probe
(22-24). The two oligonucleotides are hybridized to target
DNA and, if there is perfect complementarity, the enzyme
DNA ligase covalently joins the 5' biotinylated probe and the
3' reporter probe. If the probes and target are mismatched at
their junction, a covalent bond is not formed. Capture of the
5' biotinylated probe on immobilized streptavidin and anal-
ysis for covalently linked 3' reporters determine the nature of
the probe-target interaction (matched or mismatched). The
ligase assay uses a standard set ofconditions to distinguish all
nucleotide mismatches, and product analysis does not re-
quire electrophoresis or centrifugation (22). In this report, we
describe a strategy for automating DNA diagnosis that com-
bines target amplification by PCR with a nonisotopic analysis
of DNA sequence variants by OLA.
MATERIALS AND METHODS
Robotic Workstation. A Biomek 1000 workstation (Beck-
man) equipped with multipipet tools and a multibulk tool was
used to perform all pipetting, aspirating, and washing pro-
cedures. The workstation has been modified with a solenoid
to switch wash solutions during the ELISA. All reagents for
sample processing were stored in sterile 96-minitube cas-
settes.
DNA Samples. DNA from humans with a1-antitrypsin,
,8-globin, and cystic fibrosis variants was obtained from F.
Heijtmancik (Baylor University), from K. Tanaka (Harbor
Hospital) and J. Korenberg (Cedar-Sinai Hospital), and from
A. Osher and E. Hsu (Children's Hospital), respectively, and
prepared as described (22). DNA for amplification of human
T-cell receptor 1-chain (TCR/3) gene segments was obtained
by gently scraping cells from the lining of the buccal cavity
with a sterile toothpick. Buccal cells were dislodged into a
minitube containing 10 A.l of sterile H20, covered with 75 A.l
of mineral oil, and placed into a 96-minitube cassette for
handling by the robotic workstation. Cells were lysed with 20
p.1 of 0.1 M KOH and 0.1% Triton X-100 at 65°C for 20 min
and neutralized with 20 ,ul of 0.1 M HCl and 0.1% Triton
X-100.
Oligonucleotides. Amplification primers and ligation probes
were assembled by using standard phosphoramidite chemistry
on an Applied Biosystems 380A DNA synthesizer. Ligation
probes were modified with a 5' biotin group as described (15)
or chemically phosphorylated with 5' Phosphate-ON (Clon-
tech) according to the manufacturer's directions. Modified
probes were purified by reverse-phase high-performance liq-
uid chromatography. Phosphorylated oligonucleotide probes
(500 pmol) were labeled with dUTP-digoxigenin by mixing 100
mM potassium cacodylate, 2 mM CoC12, 200 p.M dithio-
Abbreviations: PCR, polymerase chain reaction; OLA, oligonucle-
otide ligation assay; TCRp8, T-cell receptor P chain; CFTR, cystic
fibrosis transmembrane conductance regulator; V, variable; D, di-
versity; J, joining; C, constant; STS, sequence-tagged site.
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threitol, 2.5 ,l of dUTP-digoxigenin (Boehringer Mannheim),
and 2 ul of adenosine triphosphate (40,tM) with 70 units of
terminal deoxynucleotidyltransferase (Collaborative Re-
search) for 1 hr at 370C. Free dUTP-digoxigenin was removed
by two successive ethanol precipitations.
DNA Amplification. The robotic workstation was pro-
grammed to assemble PCR reagents [5 ul containing 20 mM
Tris HCI (pH 8.3), 100mM KCI, 3mM MgCl2, 20 ng of bovine
serum albumin per ml, the four deoxynucleotide triphos-
phates each at 400,uM, 0.5 tkM amplification primers, 0.1%
Triton X-100, and 0.05 unit of Thermus aquaticus DNA
polymerase per well], genomic DNA (5,uI at 2 ng/pkl in sterile
distilled H2O containing 0.1% Triton X-100), and 70 tkl of light
mineral oil in a flexible U-bottomed 96-well microtiter plate
(Falcon). Genomic DNA samples were denatured at 93°C for
4 min and amplified by 40 cycles of 93°C for 30 sec, 55°C
[cystic fibrosis transmembrane conductance regulator
(CFTR) and TCRa constant (Ca) gene segments] or 61°C
(p-globin and a1-antitrypsin gene segments) for 45 sec, and
72°C for 90 sec in a microtiter plate thermal cycler (MJ
Research, Watertown, MA). For amplification of TCR/3 gene
segments, 15 ,1 of PCR reagents (as described above) con-
taining all six amplification primers, 15 ,u of the lysed buccal
samples, and 70 ,l of mineral oil were added to a flexible
microtiter plate. Targets were denatured at 93°C for 4 min and
amplified by 20 cycles of 30 sec at 93°C, 45 sec at 61°C, and
90 sec at 72°C. Five microliters from these reaction mixtures
was used to initiate a second round of amplification for each
of the individual TCRfl gene segments (40 cycles; 30 sec at
93°C, 45 sec at 61°C, and 90 sec at 72°C).
Ligation Assays. Ligation reaction mixtures were assem-
bled by the robotic workstation. Forty-five microliters of 0.25
M NaOH containing 0.1% Triton X-100 was added to ampli-
fied DNA samples. Ligation probes (200 fmol each) in 10 ,u
of 2x ligase buffer (100 mM Tris'HCl, pH 7.5/20 mM
MgCl2/2 mM spermidine/2 mM adenosine triphosphate/10
mM dithiothreitol) and 50% formamide were added to a
U-bottomed 96-well microtiter plate. DNA samples were
neutralized with 45 ,l of 0.25 M HCl and six 10-,p1 aliquots
were added to the microtiter plate containing the ligation
probes. Samples were covered with 70 ul of mineral oil,
denatured at 93°C for 2 min, cooled, and returned to the
workstation for the addition of 5 ,l of T4 DNA ligase (5
units/ml) (Amersham) in lx ligase buffer. Ligations were
done at room temperature (RT) for 15 min. Reactions were
stopped by adding 10 ,l of 0.25 M NaOH per well and, after
2 min at RT, 4 ,ul of 3 M sodium acetate (pH 6.5) per well.
Samples were transferred to a 96-well flat-bottomed micro-
titer plate (Falcon) coated with streptavidin [60 ,ul of strepta-
vidin (100 tkg/ml) or avidin (100 ,ug/ml) (Vector Laboratories)
for 1 hr at 37°C] and blocked 20 min (RT) before use with 200
,ul of 100 mM Tris HCI, pH 7.5/150 mM NaCI/0.05% Tween
20 (buffer A) per well with 0.5% dry milk and 100 ,ug of salmon
sperm DNA per ml. Biotinylated probes were captured at RT
for 30 min, and the plate was washed twice with 0.01 M
NaOH and 0.05% Tween 20 and once with buffer A. Thirty
microliters of anti-digoxigenin antibodies (diluted 1:1000;
Boehringer Mannheim) in buffer A with 0.5% dry milk was
added to each microtiter well. Plates were incubated 30 min
(RT) and washed six times with buffer A. Substrate (30 ,u of
BRL ELISA amplification system per well) was added, the
plates were incubated 15 min (RT), and 30 ,u of amplifier was
added. Spectrophotometric absorbances were taken at 490
nm by a Bio-Tek (Burlington, VT) plate reader and absor-
bances were directly entered into an IBM-XT computer.
Linkage Analysis. Observed haplotype frequencies were
calculated for genetic linkage analysis of TCR,8 gene seg-
ments with a myriad haplotype program (25). The probability
of linkage disequilibrium was calculated based on the x2
distribution of the Q statistic described by Hedrick et al. (26).
RESULTS
The Automated PCR/OLA Strategy. Our strategy for au-
tomated gene analysis is shown in Fig. 1. A Biomek 1000
robotic workstation was used to (i) prepare targets and
assemble reagents for DNA amplification, (ii) mix and ligate
5' biotinylated probes and 3' digoxigenin-labeled reporter
probes on amplified DNA targets using T4 DNA ligase, (iii)
capture 5' biotinylated probes on streptavidin-coated micro-
titer plates, (iv) wash plates, and (v) detect the digoxigenin
reporter coupled to biotin-labeled probes by an ELISA.
Altogether, processing time for 96 samples from entry to
computer read-out takes <7 hr. Overnight amplification
permits processing of ligation assays from 192 DNA samples
in a single day (1200 reactions, triplicates for two alleles).
Amplification Primers and Ligation Probes. A panel of
amplification primers and ligation probes for known se-
quence variants in human DNA have been synthesized (Table
1). Two sets of probes detect mutations that cause common
genetic diseases in homozygous individuals, sickle cell ane-
mia and CF (27, 28). Another set detects a common mutation
in the a1-antitrypsin gene that, in homozygous individuals,
leads to a predisposition for cirrhosis of the liver in childhood
and emphysema in adults (29). The remaining probes detect
1 Amplify Target DNA
---
2 Denature, Anneal and Ligate Modified Oligonucleotides
on Amplified Target
3 Capture Biotinylated Oligonucleotides and
Perform ELISA for Digoxigenin
FIG. 1. Schematic diagram of the steps in the automated PCR/
OLA procedure performed with a robotic workstation. The assay
contains three steps: 1, DNA target amplification; 2, analysis of
target nucleotide sequences with biotin (B)-labeled and digoxigenin
(D)-labeled oligonucleotide probes and T4 DNA ligase (L); 3, capture
of the biotin (B)-labeled probes on streptavidin (SA)-coated micro-
titer wells and analysis for covalently linked digoxigenin (D) by using
an ELISA procedure with alkaline phosphatase (AP)-conjugated
anti-digoxigenin (aD) antibodies and a substrate (S).
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Table 1. Nucleotide sequence of the amplification primers and ligation probes used in automated DNA analysis
Genomic . Target detected
region Ligation probes by
amplified Amplification primers Biotin-labeled probe Reporter-labeled probe ligation probes
P-Globin CAACTTCATCCACGTTCACCTTGCC 1. B-ATGGTGCACCTGACTCCTGA pGGAGAAGTCTGCCGTTACTG-D 1. /A
AGGGCAGGAGCCAGGGCTGGG 2. B-ATGGTGCACCTGACTCCTGT 2. AS
a1-Antitrypsin TCAGCCTTACAACGTGTCTCTGCTT 1. B-GGCTGTGCTGACCATCGACG pAGAAAGGGACTGAAGCTGCT-D 1. M
GTATGGCCTCTAAAAACATGGCCCC 2. B-GGCTGTGCTGACCATCGACA 2. Z
CFTR CAGTGGAAGAATGGCATTCTGTT 1. B-ATTAAAGAAAATATCATCTT pTGGTGTfTCCTATGATGAAT-D 1. Non-F508
GGCATGCTTTGATGACGCTTCTG 2. B-ACCATTAAAGAAAATATCAT 2. AF508
Ca CCTTGAAGCTGGGAGTGG 1. B-GAAACGAAGAAACTGAGGCCA pCACAGCTAATGAGTGAGGAAGA-D 1. C,,3A
GAGCTAAGAGAGCCGTAETGG 2. B-GAAACGAAGAAACTGAGGCCC 2. Ca,3B
V6.71 AAGGGAAAGGATGTAGAG 1. B-MACTGGTACCGACAGAGC pCTGGGGCAGGGCCTGGAGTT-D 1. Vp6.71A
CTGGCACAGAGATACACGGCC 2. B-T1TACTGGTACCGACAGAGG 2. Vp6.71B
Vp6.72 AAGGGAAAGGATGTAGAG 1. B-TCTGCAGAGAGGACTGGGGG pATCCGTCTCCACTCTGACGA-D 1. Vp6.72A
CTGGCACAGAGATACACGGCC 2. B-TCTGCAGAGAGGACTGGGGA 2. Vp6.72B
Vo1 GAGTCACACAAACCCCAAAGCACCT 1. B-AGGCCTCCAGTTCCTCATTCAG pTATTATAATGGAGAAGAGAGAGCA-D 1. VERA
GCTGCTGGCACAGAAATACAAAGCT 2. B-AGGCCTCCAGTTCCTCATTCAC 2. VERB
Cat CATTATGGTCCTTTCCCGG 1. B-ACCAGGACCAGACAGCTCTC pAGAGCAACCCTAGCCCCATTAC-D 1. C03A
AGCTCCACGTGGTCGGGGT 2. B-ACCAGGACCAGACAGCTCTr 2. C133B
Ligation reactions were performed with a mixture of a biotin-labeled and reporter-labeled probe for each specific allele.
polymorphisms in the human TCRp and TCRa loci (refs. 30
and 31; C. Whitehurst, P. Charmley, L.H., and D.A.N.,
unpublished data). Most of these probes detect single nucle-
otide substitutions in a specific DNA target. However, one
set of probes detects a 3-base-pair (bp) deletion in the gene
encoding CFTR (28) and represents a model for the detection
of sequence deletions by OLA.
Analysis of DNA Sequence Variants. As a model for DNA
diagnosis by the PCR/OLA procedure, we obtained genomic
DNAs from 32 individuals of known genotype. The robotic
workstation was used to assemble PCR reagents and genomic
DNA samples in a 96-well microtiter plate. After amplifica-
tion, ligations were performed in triplicate for each allele, and
the immobilized probes were analyzed for the presence of
digoxigenin. An example of a microtiter plate obtained from
this process is shown in Fig. 2. Amplified targets from
homozygous and heterozygous individuals for the indicated
nucleotide substitutions (,8-globin, a1-antitrypsin, and TCR
Ca) or deletion (CFTR) were used. The assay clearly iden-
tifies which alleles 1 and/or 2 (Table 1) were present in each
of the amplified samples (Fig. 2). Fig. 3 shows the mean
absorbances obtained from ligation assays on amplified DNA
targets from eight different individuals for each of the ana-
lyzed gene segments (32 individuals altogether). Mean ab-
sorbances from different individuals ranged from 0.38 to 1.17.
We have found that mean absorbances from the ligation
assays reflect the amount of target present in an amplified
DNA sample. In this regard, the colorimetric assay is quite
sensitive and can detect 3 fmol of ligated product (data not
shown). The high signal/noise ratios (10:1-200:1) obtained
with this procedure also permit simple data processing to
define the genotype of an amplified DNA sample by calcu-
lating the ratio of the mean absorbance for each allele in the
ligation assay. Furthermore, since the outcome of the PCR/
OLA procedure is based on the mean absorbance of triplicate
ligation reactions, the chance of error arising from spurious
false-negative or false-positive wells is also minimized (false-
negative or false-positive wells < 0.2% in 4000 reactions; data
not shown).
Genetic Linkage Analysis of TCR. Genes. The automated
PCR/OLA protocol has been extended to include the prep-
aration of DNA samples by the robotic workstation. Ampli-
fied DNA targets from human buccal samples were used to
determine the frequency and genetic linkage of four DNA
sequence polymorphisms in the human TCR/3 locus as shown
in Fig. 4. The human TCR,8 locus is composed of several gene
segments, variable (V), diversity (D), end joining (J), and
constant (C) genes, which span >600 kilobases (kb) ofDNA
(Fig. 4) (32, 33). Using data obtained from the automated
PCR/OLA procedure on these 96 samples, we found that two
Vp6.7 polymorphisms were in complete linkage disequilib-
rium (P < 10-14). This finding was not surprising since these
variants are separated by a small physical distance (100 bp).
Although the exact location of the V,36.7 gene segment in the
TCR,8 locus is not known, analysis of available cosmid and
YAC clones by gene-specific PCR suggests that Vp6.7 is
probably located 5' to the V1p gene segment. The three TCR
polymorphisms (V,06.7, Va1t, and C13), physically spanning at
least 600 kb, appeared to be in linkage equilibrium with one
another. Indeed, the expected haplotype frequencies calcu-
lated assuming linkage equilibrium were very close to those
observed (P < 0.81) (Table 2). These findings confirm those
recently reported in a study ofTCR polymorphisms detected
as restriction fragment length polymorphisms and may sug-
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FIG. 2. Amplified DNA targets obtained from genomic DNA samples were analyzed in triplicate by using the indicated combinations of
ligation probes (alleles 1 and 2 as described in Table 1) for each specified gene segment. Wells containing digoxigenin form a magenta-colored
product and indicate complementarity between the ligation probes and amplified DNA target.
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FIG. 3. Mean spectrophotometric absorbances (+1 SD) from
triplicate ligation reactions performed by the automated PCR/OLA
procedure on amplified DNA samples obtained from eight donors for
each gene analyzed (32 DNA samples total).
gest that hot spots of recombination exist in the TCRj3 locus
(34).
DISCUSSION
Automated analysis of DNA polymorphisms and variants by
PCR/OLA has many advantages over existing approaches to
DNA diagnostics. Small numbers of cells (cheek scraping) or
DNA samples (10 ng) are sufficient for analysis. Only small
fragments of DNA (a few hundred base pairs) are required.
Therefore, partially degraded DNA is still useful. The re-
agents are stable and easily obtained, and nonisotopic re-
porter groups are used. The entire assay is performed in
microtiter wells, thus avoiding the use of centrifugation or
electrophoresis. The assay yields high signal/noise ratios and
a simple readout that is easily transferred to a computer for
storage and analysis; no measurements of DNA fragment
sizes are necessary. All of the tested sequence variants
(nucleotide transitions and transversions, and a deletion)
could be discriminated by OLA using a standard set of
conditions. The initial PCR amplification facilitates the dis-
crimination of polymorphisms in individual members of a
multigene family (e.g., the TCR V136.7 gene segment is one of
13 8.4 13 13
Gentomee.-.-..iuI/9 7 4 2! 10 11] 1*4 6 11 8.5136566 65C ntromeree -- fi;
6.~~~~~~~~~~~I
Frequency Frequency
A: C G 66% A: G 83%
B: G A 34% B: C 17%
Table 2. TCR haplotypes
Haplotype









Expected haplotypes were calculated assuming random allelic
association-e.g., AAA = 0.66 x 0.83 x 0.66 x 192 = 69.
nine highly similar members of the V,06 subfamily). The two
successive levels of sequence discrimination, PCR and then
OLA, enhance signal/noise ratios and reduce the likelihood
of error, particularly in the analysis of polymorphisms in
multigene families. The steps in the assay are automatable,
eliminating the need for human intervention (and possible
mistakes) in a tedious and repetitious process. With automa-
tion, high throughput is possible. At present, we can process
1200 ligation reactions per day with a single operator and
robotic workstation, and, in the near future, further automa-
tion with a robotic arm will permit processing of 6000
reactions per day.
The automated PCR/OLA assay can be applied in many
different basic research and clinical areas. Genetic diseases
fall into several different categories including the common
and widespread mutations of sickle cell disease, a,-
antitrypsin or CF, and newly arising spontaneous mutations
such as Lesch-Nyhan disease (35). Clearly, PCR/OLA fa-
cilitates the analysis of the common mutations, either in
screening at-risk members of families with diseases or for
more general carrier screening purposes. Rapid techniques
are being developed to identify the sequence variations of
newly arising mutations (35, 36). Once identified, the com-
bined PCR/OLA procedure can be used to follow the inher-
itance of these specific mutations in affected families. Many
genes cause a predisposition toward disease. This is true of
the a1-antitrypsin mutation described above. Recently, it has
been demonstrated that certain TCR and HLA haplotypes
may predispose humans to certain autoimmune diseases such
as multiple sclerosis (37-39). Therapeutic strategies are being
developed to circumvent these predispositions (40-42).
Therefore, automated screening may be useful in the near










FIG. 4. Schematic diagram of the human TCR,8 locus giving the relative order of the V, D, J, and C gene segments. DNA polymorphisms
in three indicated gene segments were analyzed in 96 individuals. Their location, where known, is shown (arrow up). The nucleotide substitutions
analyzed and the frequency for each variant in these samples are shown.
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positions in which some form of preventive therapy can be
initiated.
The automated PCR/OLA procedure provides a powerful
approach to high-resolution genetic linkage mapping of the
human genome or other complex genomes. For this ap-
proatch, sequence-tagged sites (STSs) (43) from specific chro-
mosomal regions (e.g., the TCR,8 locus) or from a specific
chromosome (e.g., STSs obtained from random clones of a
flow-sorted chromosome library) would be scanned for in-
ternal DNA sequence polymorphisms (9-11) to obtain a set
of polymorphic STSs. Once acquired, polymorphic STSs can
be rapidly ordered by analysis of large multigeneration fam-
ilies or by single-sperm typing (44, 45) using the automated
PCR/OLA system.
The availability of human polymorphic STSs will also
provide a set of markers for automated forensic typing. For
example, with a set of maximally informative biallelic mark-
ers (50:50 distribution in random mating populations) from
each of the 22 human autosomes, the probability that two
individuals would have identical DNA fingerprints-i.e., the
same set of the 44 alleles-is -1 in 1010. The automated
PCR/OLA procedure eliminates most of the limitations as-
sociated with forensic typing by conventional Southern blot
analysis (e.g., the measurement of DNA fragment sizes, the
requirement for high quality DNA, and the use of radioiso-
topes).
Other applications for automated DNA diagnosis by the
PCR/OLA procedure include HLA typing, the analysis of
recessive or dominant oncogenes, and the identification of
infectious -pathogens. The use of commercially available
thermostable ligases and automated ligation amplification
reactions in the direct detection of single copy genes can also
be explored. Moreover, multiple nonisotopic reporter groups
may be developed that will be simultaneously analyzed in a
single microtiter well. This raises the possibility of multi-
plexing the OLA procedure to the point where initially both
alleles can be analyzed together and eventually multiple
biallelic loci can be typed in a single well. These and other
improvements, such as a single instrument to perform the
entire analysis, will greatly increase the throughput and
potential applications of automated DNA diagnostics.
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